NovoCure Limited
NVCR
$15.21
$3.2827.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 655.35M | 642.27M | 630.16M | 621.71M | 605.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 655.35M | 642.27M | 630.16M | 621.71M | 605.22M |
| Cost of Revenue | 165.17M | 157.18M | 147.83M | 141.01M | 136.18M |
| Gross Profit | 490.18M | 485.09M | 482.34M | 480.70M | 469.05M |
| SG&A Expenses | 416.23M | 444.27M | 439.73M | 433.04M | 427.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 805.94M | 816.02M | 799.99M | 785.60M | 772.76M |
| Operating Income | -150.59M | -173.75M | -169.83M | -163.88M | -167.54M |
| Income Before Tax | -136.25M | -150.50M | -142.07M | -129.82M | -131.16M |
| Income Tax Expenses | -23.00K | 27.15M | 28.89M | 34.37M | 37.47M |
| Earnings from Continuing Operations | -136.23 | -177.65 | -170.95 | -164.19 | -168.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.23M | -177.65M | -170.95M | -164.19M | -168.63M |
| EBIT | -150.59M | -173.75M | -169.83M | -163.88M | -167.54M |
| EBITDA | -137.46M | -161.59M | -158.86M | -153.51M | -157.67M |
| EPS Basic | -1.22 | -1.61 | -1.56 | -1.51 | -1.56 |
| Normalized Basic EPS | -0.90 | -1.00 | -0.96 | -0.90 | -0.91 |
| EPS Diluted | -1.22 | -1.61 | -1.56 | -1.51 | -1.56 |
| Normalized Diluted EPS | -0.90 | -1.00 | -0.96 | -0.90 | -0.91 |
| Average Basic Shares Outstanding | 446.01M | 442.24M | 438.58M | 434.70M | 431.69M |
| Average Diluted Shares Outstanding | 446.01M | 442.24M | 438.58M | 434.70M | 431.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |